Home LiteratureArticle Details
PMID: 8160775 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.

The American journal of pathology ·Vol. 144 ·No. 4 ·1994-04-00 ·Pages 756-66

Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ

Abstract

To understand better the role of physical p53 deletion in bladder cancer, 106 formalin-fixed and 45 unfixed bladder tumors were examined using fluorescence in situ hybridization. Probes for centromere 17 and the p53 locus were hybridized simultaneously to interphase tumor cells to analyze p53 and chromosome 17 copy number on a cell by cell basis. 17p deletion was found in four of 43 pTa tumors, 18 of 43 pT1 tumors and 29 of 58 pT2-4 tumors (P = 0.0001). 17p deletion was also highly correlated with grade (P = 0.0001) and with p53 immunostaining (P = 0.0005). Chromosome 17 polysomy was associated with stage, grade, 17p deletions, and p53 immunostaining (P = 0.0001). The strong difference in centromere 17 copy number and 17p deletions between pTa and pT1 tumors supports a relevant biological distinction between pTa and pT1 tumors.

MeSH Terms
Alleles Base Sequence Chromosome Deletion Chromosomes, Human, Pair 17 DNA/biosynthesis DNA Probes Gene Deletion Genes, p53/genetics Humans In Situ Hybridization, Fluorescence Molecular Sequence Data Tumor Suppressor Protein p53/metabolism Urinary Bladder Neoplasms/genetics,metabolism,pathology
Chemicals
DNA Probes Tumor Suppressor Protein p53 DNA
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Sauter G
Department of Laboratory Medicine, University of California, San Francisco.
Deng G
Moch H
Kerschmann R
Matsumura K
De Vries S
George T
Fuentes J
Carroll P
Mihatsch M J
References (46)
46 references, click to expand
  1. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction.
    Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4976-80 PMID: 2052580
  2. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer.
    Cancer Res. 1990 Jan 1;50(1):44-7 PMID: 2293558
  3. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer.
    Jpn J Cancer Res. 1991 Jul;82(7):835-40 PMID: 1679056
  4. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
    Oncogene. 1991 Sep;6(9):1699-703 PMID: 1923535
  5. A DNA binding domain is contained in the C-terminus of wild type p53 protein.
    Nucleic Acids Res. 1991 Oct 11;19(19):5191-8 PMID: 1923804
  6. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas.
    Cytometry. 1991;12(5):438-44 PMID: 1935458
  7. Tumor suppressor genes.
    Science. 1991 Nov 22;254(5035):1138-46 PMID: 1659741
  8. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
    Br J Cancer. 1991 Dec;64(6):1076-82 PMID: 1764370
  9. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.
    Br J Cancer. 1992 Jan;65(1):40-4 PMID: 1310251
  10. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters.
    Int J Cancer. 1992 Feb 20;50(4):528-32 PMID: 1537617
  11. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis.
    Am J Hum Genet. 1992 Mar;50(3):584-9 PMID: 1347196
  12. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.
    Cancer Res. 1992 Mar 15;52(6):1427-33 PMID: 1347252
  13. p53 mutations in human lung tumors.
    Cancer Res. 1992 Apr 1;52(7):1695-8 PMID: 1312896
  14. Expression of p53 and 17p allelic loss in colorectal carcinoma.
    Cancer Res. 1992 Apr 1;52(7):1974-80 PMID: 1551126
  15. Factors affecting survival in primary superficial bladder cancer.
    Eur Urol. 1990;17(2):113-8 PMID: 2311636
  16. Increased expression of mutant forms of p53 oncogene in primary lung cancer.
    Lancet. 1990 Mar 24;335(8691):675-9 PMID: 1969059
  17. Biology and management of bladder cancer.
    N Engl J Med. 1990 Apr 19;322(16):1129-38 PMID: 2181313
  18. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
    Oncogene. 1990 Jun;5(6):893-9 PMID: 1694291
  19. Suppression of human colorectal carcinoma cell growth by wild-type p53.
    Science. 1990 Aug 24;249(4971):912-5 PMID: 2144057
  20. Presence of a potent transcription activating sequence in the p53 protein.
    Science. 1990 Aug 31;249(4972):1046-9 PMID: 2144363
  21. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis.
    Lancet. 1990 Sep 29;336(8718):761-3 PMID: 1976143
  22. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder.
    Cancer Res. 1990 Nov 1;50(21):7081-3 PMID: 2208176
  23. p53 in colorectal cancer: clinicopathological correlation and prognostic significance.
    Br J Cancer. 1991 Feb;63(2):317-9 PMID: 1997114
  24. The p53 tumor suppressor gene and gene product.
    Princess Takamatsu Symp. 1989;20:221-30 PMID: 2488233
  25. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas.
    Oncogene. 1991 Mar;6(3):413-21 PMID: 2011397
  26. p53 expression in colorectal tumors.
    Am J Pathol. 1991 Apr;138(4):807-13 PMID: 1707233
  27. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer.
    Proc Natl Acad Sci U S A. 1991 May 1;88(9):3847-51 PMID: 1673792
  28. Identification of p53 gene mutations in bladder cancers and urine samples.
    Science. 1991 May 3;252(5006):706-9 PMID: 2024123
  29. Overexpression and mutation of p53 in epithelial ovarian cancer.
    Cancer Res. 1991 Jun 1;51(11):2979-84 PMID: 2032235
  30. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
    Cell. 1991 May 31;65(5):765-74 PMID: 2040013
  31. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.
    Oncogene. 1992 Apr;7(4):743-9 PMID: 1565469
  32. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
    J Natl Cancer Inst. 1992 Jun 3;84(11):845-55 PMID: 1317462
  33. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors.
    Cancer Res. 1992 Jun 15;52(12):3391-5 PMID: 1596898
  34. Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization.
    Cancer Res. 1992 Jun 15;52(12):3474-7 PMID: 1350754
  35. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
    Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 PMID: 1351679
  36. Cancer. p53, guardian of the genome.
    Nature. 1992 Jul 2;358(6381):15-6 PMID: 1614522
  37. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
    J Natl Cancer Inst. 1992 Jul 15;84(14):1109-14 PMID: 1352359
  38. Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype.
    J Urol. 1992 Nov;148(5):1595-9 PMID: 1433575
  39. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    J Natl Cancer Inst. 1993 Jan 6;85(1):53-9 PMID: 7677935
  40. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder.
    Mod Pathol. 1993 Jan;6(1):20-4 PMID: 8093979
  41. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.
    J Histochem Cytochem. 1981 Apr;29(4):577-80 PMID: 6166661
  42. Localization of gene for human p53 tumour antigen to band 17p13.
    Nature. 1986 Mar 6-12;320(6057):84-5 PMID: 3456488
  43. P53 expression in breast cancer.
    Int J Cancer. 1988 Feb 15;41(2):178-83 PMID: 3276632
  44. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.
    Mol Cell Biol. 1988 Feb;8(2):531-9 PMID: 2832726
  45. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
    J Virol. 1989 Feb;63(2):739-46 PMID: 2642977
  46. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.
    Br J Cancer. 1991 Jun;63(6):967-70 PMID: 1712624
Article Info
Journal
The American journal of pathology
Abbr.
Am J Pathol
ISSN
0002-9440
Published
1994-04-00
Pages
756-66
Language
English
Region
United States
NLM ID
0370502
PMCID
PMC1887234
Subset
IM
Grants
NCI NIH HHS · CA47537 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com